Retrospective comparative analysis of cardiovascular implantable electronic device infections with and without the use of antibacterial envelopes

A. Hassoun, E. D. Thottacherry, M. Raja, M. Scully, Amir Azarbal

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Cardiovascular implantable electronic device (CIED) infections are associated with morbidity and mortality. Peri-operative systemic intravenous antibiotic prophylaxis reduces the rate of CIED infections. AIGISRx, a polymer envelope implanted with the CIED, releases minocycline and rifampin, and has been introduced to reduce infections. Methods Retrospective review of 184 patients who underwent CIED implantation was conducted. Ninety-two patients were implanted with an AIGISRx envelope (AIGISRx group) and 92 patients were not implanted with an AIGISRx envelope (control group). Data were collected on demographics and risk factors for CIED infections (i.e. congestive heart failure, renal insufficiency, chronic kidney disease, oral anticoagulant use, chronic steroid use, need for lead replacement or revision, temporary pacing, early re-intervention, and having more than two leads in place). Rates of implantation success, major infections and mortality were compared between the AIGISRx group and the control group. Results The AIGISRx group had longer hospitalizations (6.8 ± 10.7 days vs 3.1 ± 5.2 days; P = 0.001), higher chronic corticosteroid use, higher rates of replacement or revision (51.1% vs 8.7%; P = 0.001), and a greater proportion of devices with more than two intracardiac leads (42.4% vs 29.3%; P = 0.03) than the control group. Successful implantation occurred in 97% of patients in both groups. Major infection was seen in 5.4% of cases in the AIGISRx group and 1.1% of cases in the control group (P = 0.048). Device removal was conducted in 3.3% of cases in the AIGISRx group compared with 1.1% of cases in the control group (P = 0.16). There were two deaths in the AIGISRx group. Organisms cultured were meticillin-resistant Staphylococcus aureus, meticillin-susceptible S. aureus and Enterococcus faecalis. Conclusion The AIGISRx group had higher rates of major infection but also higher risk factors compared with the control group. The rate of device extraction and CIED-related mortality was higher in the AIGISRx group than in the control group.

Original languageEnglish (US)
Pages (from-to)286-291
Number of pages6
JournalJournal of Hospital Infection
Volume95
Issue number3
DOIs
StatePublished - Mar 1 2017
Externally publishedYes

Fingerprint

Equipment and Supplies
Control Groups
Infection
Methicillin
Staphylococcus aureus
Mortality
Device Removal
Minocycline
Antibiotic Prophylaxis
Enterococcus faecalis
Rifampin
Chronic Renal Insufficiency
Anticoagulants
Renal Insufficiency
Adrenal Cortex Hormones
Polymers
Hospitalization
Heart Failure
Steroids
Demography

Keywords

  • Cardiac implantable device
  • Complications
  • Infection

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Retrospective comparative analysis of cardiovascular implantable electronic device infections with and without the use of antibacterial envelopes. / Hassoun, A.; Thottacherry, E. D.; Raja, M.; Scully, M.; Azarbal, Amir.

In: Journal of Hospital Infection, Vol. 95, No. 3, 01.03.2017, p. 286-291.

Research output: Contribution to journalArticle

@article{47d574c7e3114693b193437050630a80,
title = "Retrospective comparative analysis of cardiovascular implantable electronic device infections with and without the use of antibacterial envelopes",
abstract = "Background Cardiovascular implantable electronic device (CIED) infections are associated with morbidity and mortality. Peri-operative systemic intravenous antibiotic prophylaxis reduces the rate of CIED infections. AIGISRx, a polymer envelope implanted with the CIED, releases minocycline and rifampin, and has been introduced to reduce infections. Methods Retrospective review of 184 patients who underwent CIED implantation was conducted. Ninety-two patients were implanted with an AIGISRx envelope (AIGISRx group) and 92 patients were not implanted with an AIGISRx envelope (control group). Data were collected on demographics and risk factors for CIED infections (i.e. congestive heart failure, renal insufficiency, chronic kidney disease, oral anticoagulant use, chronic steroid use, need for lead replacement or revision, temporary pacing, early re-intervention, and having more than two leads in place). Rates of implantation success, major infections and mortality were compared between the AIGISRx group and the control group. Results The AIGISRx group had longer hospitalizations (6.8 ± 10.7 days vs 3.1 ± 5.2 days; P = 0.001), higher chronic corticosteroid use, higher rates of replacement or revision (51.1{\%} vs 8.7{\%}; P = 0.001), and a greater proportion of devices with more than two intracardiac leads (42.4{\%} vs 29.3{\%}; P = 0.03) than the control group. Successful implantation occurred in 97{\%} of patients in both groups. Major infection was seen in 5.4{\%} of cases in the AIGISRx group and 1.1{\%} of cases in the control group (P = 0.048). Device removal was conducted in 3.3{\%} of cases in the AIGISRx group compared with 1.1{\%} of cases in the control group (P = 0.16). There were two deaths in the AIGISRx group. Organisms cultured were meticillin-resistant Staphylococcus aureus, meticillin-susceptible S. aureus and Enterococcus faecalis. Conclusion The AIGISRx group had higher rates of major infection but also higher risk factors compared with the control group. The rate of device extraction and CIED-related mortality was higher in the AIGISRx group than in the control group.",
keywords = "Cardiac implantable device, Complications, Infection",
author = "A. Hassoun and Thottacherry, {E. D.} and M. Raja and M. Scully and Amir Azarbal",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.jhin.2016.12.014",
language = "English (US)",
volume = "95",
pages = "286--291",
journal = "Journal of Hospital Infection",
issn = "0195-6701",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Retrospective comparative analysis of cardiovascular implantable electronic device infections with and without the use of antibacterial envelopes

AU - Hassoun, A.

AU - Thottacherry, E. D.

AU - Raja, M.

AU - Scully, M.

AU - Azarbal, Amir

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background Cardiovascular implantable electronic device (CIED) infections are associated with morbidity and mortality. Peri-operative systemic intravenous antibiotic prophylaxis reduces the rate of CIED infections. AIGISRx, a polymer envelope implanted with the CIED, releases minocycline and rifampin, and has been introduced to reduce infections. Methods Retrospective review of 184 patients who underwent CIED implantation was conducted. Ninety-two patients were implanted with an AIGISRx envelope (AIGISRx group) and 92 patients were not implanted with an AIGISRx envelope (control group). Data were collected on demographics and risk factors for CIED infections (i.e. congestive heart failure, renal insufficiency, chronic kidney disease, oral anticoagulant use, chronic steroid use, need for lead replacement or revision, temporary pacing, early re-intervention, and having more than two leads in place). Rates of implantation success, major infections and mortality were compared between the AIGISRx group and the control group. Results The AIGISRx group had longer hospitalizations (6.8 ± 10.7 days vs 3.1 ± 5.2 days; P = 0.001), higher chronic corticosteroid use, higher rates of replacement or revision (51.1% vs 8.7%; P = 0.001), and a greater proportion of devices with more than two intracardiac leads (42.4% vs 29.3%; P = 0.03) than the control group. Successful implantation occurred in 97% of patients in both groups. Major infection was seen in 5.4% of cases in the AIGISRx group and 1.1% of cases in the control group (P = 0.048). Device removal was conducted in 3.3% of cases in the AIGISRx group compared with 1.1% of cases in the control group (P = 0.16). There were two deaths in the AIGISRx group. Organisms cultured were meticillin-resistant Staphylococcus aureus, meticillin-susceptible S. aureus and Enterococcus faecalis. Conclusion The AIGISRx group had higher rates of major infection but also higher risk factors compared with the control group. The rate of device extraction and CIED-related mortality was higher in the AIGISRx group than in the control group.

AB - Background Cardiovascular implantable electronic device (CIED) infections are associated with morbidity and mortality. Peri-operative systemic intravenous antibiotic prophylaxis reduces the rate of CIED infections. AIGISRx, a polymer envelope implanted with the CIED, releases minocycline and rifampin, and has been introduced to reduce infections. Methods Retrospective review of 184 patients who underwent CIED implantation was conducted. Ninety-two patients were implanted with an AIGISRx envelope (AIGISRx group) and 92 patients were not implanted with an AIGISRx envelope (control group). Data were collected on demographics and risk factors for CIED infections (i.e. congestive heart failure, renal insufficiency, chronic kidney disease, oral anticoagulant use, chronic steroid use, need for lead replacement or revision, temporary pacing, early re-intervention, and having more than two leads in place). Rates of implantation success, major infections and mortality were compared between the AIGISRx group and the control group. Results The AIGISRx group had longer hospitalizations (6.8 ± 10.7 days vs 3.1 ± 5.2 days; P = 0.001), higher chronic corticosteroid use, higher rates of replacement or revision (51.1% vs 8.7%; P = 0.001), and a greater proportion of devices with more than two intracardiac leads (42.4% vs 29.3%; P = 0.03) than the control group. Successful implantation occurred in 97% of patients in both groups. Major infection was seen in 5.4% of cases in the AIGISRx group and 1.1% of cases in the control group (P = 0.048). Device removal was conducted in 3.3% of cases in the AIGISRx group compared with 1.1% of cases in the control group (P = 0.16). There were two deaths in the AIGISRx group. Organisms cultured were meticillin-resistant Staphylococcus aureus, meticillin-susceptible S. aureus and Enterococcus faecalis. Conclusion The AIGISRx group had higher rates of major infection but also higher risk factors compared with the control group. The rate of device extraction and CIED-related mortality was higher in the AIGISRx group than in the control group.

KW - Cardiac implantable device

KW - Complications

KW - Infection

UR - http://www.scopus.com/inward/record.url?scp=85010506578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010506578&partnerID=8YFLogxK

U2 - 10.1016/j.jhin.2016.12.014

DO - 10.1016/j.jhin.2016.12.014

M3 - Article

VL - 95

SP - 286

EP - 291

JO - Journal of Hospital Infection

JF - Journal of Hospital Infection

SN - 0195-6701

IS - 3

ER -